TargetBeta
IDH1
isocitrate dehydrogenase (NADP(+)) 1 · Isocitrate dehydrogenases
6 programs in company-led studies act on IDH1, from 5 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 53 running | – | NCIt |
| ivosidenibrule | Agios Pharmaceuticals | phase 3 | 135 running | – | NCIt |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 124 running | IDH2 | NCIt |
| safusidenibrule | Nuvation Bio | phase 3 | 64 running | – | NCIt |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 54 running | – | the company's pipeline |
| ranosidenibrule | HUTCHMED | phase 3 | 73 running | IDH2 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myeloid, Acute, 5 programs
- Glioma, 4 programs
- Astrocytoma, 3 programs
- Cholangiocarcinoma, 3 programs
- Glioblastoma, 1 program
- Neoplasm Metastasis, 1 program
- Neoplasms, Unknown Primary, 1 program
- Oligodendroglioma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 23, 2026vorasidenib · Agios Pharmaceuticals · phase 3 · NCT07250633
- Dec 2026IDH1 Inhibitor TQB3454 · Sino Biopharmaceutical · phase 3 · NCT05987358
- Dec 2026ranosidenib · HUTCHMED · phase 3 · NCT07025018
- Apr 30, 2027olutasidenib · Rigel Pharmaceuticals · phase 4 · NCT07486713
- Oct 15, 2027ivosidenib · Agios Pharmaceuticals · phase 3 · NCT05907057
- Dec 1, 2028safusidenib · Nuvation Bio · phase 3 · NCT05303519
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.